On this page
Back to topAktis Oncology AKTS
Aktis Oncology listed on Nasdaq on 9 Jan 2026 and is not in the S&P 500. It is worth $915 million. Its price history starts on 9 Jan 2026. Its board has 9 directors, 6 of them independent. 4 other officers are on file. At 30 Jun 2026, Mpm Bioimpact was its largest institutional holder, with 8.8% of the company.
- CEO
- Matthew Roden
- Chair
- Todd Foley
- Listed
- 9 Jan 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Boston, MA
- Market cap
- $915M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Financial history
Twelve months to 30 Sep 2026, from Aktis Oncology's quarterly filings.
Quarters since Mar 2025
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Mar 2025 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $4M | $-30M |
| Jun 2026 | $3M | $-24M |
| Mar 2026 | $3M | $-18M |
| Sep 2025 | $2M | $-16M |
| Jun 2025 | $2M | $-18M |
| Mar 2025 | $1M | $-15M |
Aktis Oncology's market cap since January 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $930M |
Download Aktis Oncology's data as JSON, with the weekly market caps in billions of dollars from 9 Jan 2026.
Board and leadership
Board and officers
Board from the proxy filed 30 Mar 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (9) | |||||
| Todd FoleyChairNot independent 路 since 2020 路 Compensation (chair), Nominating and Corporate Governance (chair)Managing Director, MPM BioImpact LLC | |||||
| Matthew RodenPresident and CEONot independent 路 since 2020 | |||||
| Glenn GormleyDirector | |||||
| Ken HerrmannDirectorIndependent 路 since 2024 路 Nominating and Corporate GovernanceDirector and Chair of the Department of Nuclear Medicine, Universit盲tsmedizin Essen | |||||
| Helen Susan KimDirectorIndependent 路 since 2021 路 Nominating and Corporate GovernanceSenior Managing Director, Vida Ventures, LLCOther boards: Prothena Corporation plc | |||||
| Oleg NodelmanDirectorIndependent 路 since 2021Founder and Portfolio Manager, EcoR1 Capital, LLCOther boards: AnaptysBio, Galapagos NV and Zymeworks | |||||
| Lloyd Mitchell SegalDirectorIndependent 路 since 2021 路 Audit, Nominating and Corporate GovernanceCo-founder, Repare Therapeutics, Inc. | |||||
| Michael A. ShermanDirectorIndependent 路 since 2025 路 Audit, CompensationDirector, Werewolf Therapeutics, Inc.Other boards: Werewolf Therapeutics | |||||
| Mary ThistleDirectorIndependent 路 since 2025 路 Audit (chair), CompensationFormer Special Advisor, Bill & Melinda Gates Medical Research InstituteOther boards: Cullinan Therapeutics, Q32 Bio, Entrada Therapeutics and Vigil Neuroscience | |||||
| Officers (4) | |||||
| Kyle D. KuvalankaChief Financial OfficerLast filed 8 Jan 2026 | |||||
| Akos CzibereChief Medical OfficerLast filed 24 Sep 2026 | |||||
| Paul L. FeldmanChief Scientific OfficerLast filed 8 Jan 2026 | |||||
| Shulamit Ron-BiggerChief Operating OfficerLast filed 10 Jul 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Aktis Oncology. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $3.2 million of stock in 5 sales and bought $59.2 million in 3 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 23 Sep 2026Sale | Akos CzibereChief Medical Officer | $259K |
| 20 Jul 2026Sale | Ken HerrmannDirector | $119K |
| 17 Jul 2026Sale | Ken HerrmannDirector | $77K |
| 8 Jul 2026Sale | Akos CzibereChief Medical Officer | $1.4M |
| 8 Jul 2026Sale | Shulamit Ron-BiggerChief Operating Officer | $1.4M |
| 12 Jan 2026Buy | Oleg NodelmanDirector | $40M |
| 12 Jan 2026Buy | Helen Susan KimDirector | $15M |
| 12 Jan 2026Buy | Todd FoleyChair | $4.2M |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
2 departures and 1 appointment of directors and officers and 2 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of Aktis Oncology's insider sales.
Events, newest first
- 8 Jul 2026 Akos Czibere sold $1.4MChief Medical Officer
- 8 Jul 2026 Shulamit Ron-Bigger sold $1.4MChief Operating Officer
- 15 Apr 2026 Oleg Nodelman resignedMember of the Board, effective 20 May 2026
- 15 Apr 2026 Helen S. Kim resignedMember of the Board, effective 20 May 2026
- 15 Apr 2026 Glenn Gormley appointedClass I director
| Date | Event | Filing |
|---|---|---|
| 8 Jul 2026 | Akos Czibere sold $1.4MChief Medical Officer | Form 4 |
| 8 Jul 2026 | Shulamit Ron-Bigger sold $1.4MChief Operating Officer | Form 4 |
| 15 Apr 2026 | Oleg Nodelman resignedMember of the Board, effective 20 May 2026 | 8-K |
| 15 Apr 2026 | Helen S. Kim resignedMember of the Board, effective 20 May 2026 | 8-K |
| 15 Apr 2026 | Glenn Gormley appointedClass I director | 8-K |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.